RxDoctor Payments Data

Madhavi Chilakamarri, MD

Internal Medicine · Fort Wayne, INNPI 1013916394

Payments from drug & device makers

$522in general payments, 2019–2025

Across 25 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$214
  • Novartis$69
  • AbbVie$47
  • AstraZeneca$45
  • Boston Scientific$34
  • GSK$33
  • plus $80 from 4 others

What the payments were for

  • Food & beverage$522100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk6$214
Novartis4$69
AbbVie(2 entities)3$47
AstraZeneca3$45
Boston Scientific1$34
GSK2$33
Pfizer2$27
Genentech USA, Inc.2$22
Abbott1$17
Amgen1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$522 in reported general payments places this provider in the 65th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$96,014
Medicare patients
232
Services billed
3,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide166$243,789
EliquisApixaban63$73,058
JanuviaSitagliptin Phosphate45$68,991
JardianceEmpagliflozin44$65,392
MounjaroTirzepatide44$57,126
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$30,981
XareltoRivaroxaban22$26,729
Tresiba Flextouch U-200Insulin Degludec12$23,781
FarxigaDapagliflozin Propanediol20$23,020
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$20,605
Tresiba Flextouch U-100Insulin Degludec12$19,193
TrulicityDulaglutide16$18,773
Repatha SureclickEvolocumab14$17,321
Spiriva HandihalerTiotropium Bromide18$14,604
MyrbetriqMirabegron12$14,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$214$243,789166 claims
PfizerEliquis$27$73,05863 claims
GSKTrelegy Ellipta, Breo Ellipta$33$43,01354 claims
AstraZenecaFarxiga$45$23,02020 claims
AbbVieSynthroid$47$1,96857 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →